| Year |
Citation |
Score |
| 2018 |
Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, et al. Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer Discovery. PMID 29610121 DOI: 10.1158/2159-8290.Cd-17-1004 |
0.39 |
|
| 2017 |
Kivioja JL, Lopez Martí JM, Kumar A, Kontro M, Edgren H, Parsons A, Lundán T, Wolf M, Porkka K, Heckman CA. Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia. Leukemia & Lymphoma. 1-8. PMID 28776436 DOI: 10.1080/10428194.2017.1357174 |
0.301 |
|
| 2017 |
Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK. Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer (Dove Medical Press). 9: 185-198. PMID 28356768 DOI: 10.2147/BCTT.S115600 |
0.317 |
|
| 2016 |
Eldfors S, Kuusanmäki H, Kontro M, Majumder MM, Parsons A, Edgren H, Pemovska T, Kallioniemi O, Wennerberg K, Gökbuget N, Burmeister T, Porkka K, Heckman CA. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. Leukemia. PMID 27461063 DOI: 10.1038/Leu.2016.202 |
0.407 |
|
| 2016 |
Kangaspeska S, Hultsch S, Jaiswal A, Edgren H, Mpindi J, Eldfors S, Brück O, Aittokallio T, Kallioniemi O. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. Bmc Cancer. 16: 378-378. PMID 27378269 DOI: 10.1186/S12885-016-2452-5 |
0.374 |
|
| 2016 |
Tumiati M, Munne PM, Edgren H, Eldfors S, Hemmes A, Kuznetsov SG. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers. Oncogene. PMID 26820992 DOI: 10.1038/Onc.2015.528 |
0.429 |
|
| 2016 |
Edgren H, Ruusulehto A, Ojala K, Laaksonen M. Abstract 4505: Pan-cancer analysis of fusion gene druggability and neoantigen potential Cancer Research. 76: 4505-4505. DOI: 10.1158/1538-7445.Am2016-4505 |
0.475 |
|
| 2016 |
Ojamies PN, Kontro M, Edgren H, Ellonen P, Lagstrom S, Almusa H, Miettinen T, Eldfors S, Tamborero D, Wennerberg K, Heckman C, Porkka K, Wolf M, Kallioniemi O. Abstract 2378: Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing Cancer Research. 76: 2378-2378. DOI: 10.1158/1538-7445.Am2016-2378 |
0.445 |
|
| 2015 |
Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, et al. Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2. Cancer Discovery. 5: 506-19. PMID 25716347 DOI: 10.1158/2159-8290.Cd-14-1042 |
0.423 |
|
| 2015 |
Edgren H, Ojala K, Ruusulehto A, Ganji G. Abstract 4793: Rapid pan-cancer identification of previously unidentified fusion genes to enable novel targeted therapeutics Cancer Research. 75: 4793-4793. DOI: 10.1158/1538-7445.Am2015-4793 |
0.474 |
|
| 2015 |
Edgren H, Ojala K, Ruusulehto A. Abstract A75: Pan-cancer identification of fusion genes as therapeutic targets in cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A75 |
0.455 |
|
| 2014 |
Andersson E, Eldfors S, Edgren H, Ellonen P, Väkevä L, Ranki A, Mustjoki S. Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing. Experimental Dermatology. 23: 366-8. PMID 24689486 DOI: 10.1111/Exd.12405 |
0.4 |
|
| 2014 |
Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagström S, Lohi O, Lundán T, Martí JM, Majumder MM, et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 28: 1738-42. PMID 24573384 DOI: 10.1038/Leu.2014.89 |
0.309 |
|
| 2014 |
Ojamies NP, Kontro M, Wolf M, Edgren H, Ellonen P, Lagström S, Hannunen T, Pemovska T, Almusa H, Lepistö M, Heckman CA, Wennerberg K, Porkka K, Kallioniemi O. Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse Blood. 124: 1022-1022. DOI: 10.1182/Blood.V124.21.1022.1022 |
0.424 |
|
| 2014 |
Ojamies NP, Kontro M, Edgren H, Eldfors S, Ellonen P, Pemovska T, Sonja L, Almusa H, Lepisto M, Aittokallio T, Wennerberg K, Heckman C, Porkka K, Kallioniemi O. Abstract 982: Analysis of clonal evolution of leukemia in vivo following novel targeted treatments Cancer Research. 74: 982-982. DOI: 10.1158/1538-7445.Am2014-982 |
0.468 |
|
| 2013 |
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery. 3: 1416-29. PMID 24056683 DOI: 10.1158/2159-8290.Cd-13-0350 |
0.414 |
|
| 2013 |
Högnäs G, Hämälistö S, Rilla K, Laine JO, Vilkki V, Murumägi A, Edgren H, Kallioniemi O, Ivaska J. Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. Carcinogenesis. 34: 2000-9. PMID 23689353 DOI: 10.1093/Carcin/Bgt171 |
0.381 |
|
| 2013 |
Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Børresen-Dale AL, Perälä M, Kallioniemi O. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Molecular Oncology. 7: 392-401. PMID 23253899 DOI: 10.1016/J.Molonc.2012.10.012 |
0.449 |
|
| 2013 |
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov M, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, et al. Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling Blood. 122: 482-482. DOI: 10.1182/Blood.V122.21.482.482 |
0.412 |
|
| 2013 |
Kuusanmäki H, Eldfors S, Pemovska T, Rajala HLM, Edgren H, Ellonen P, Lagström S, Lundán T, Kallioniemi O, Mustjoki S, Porkka K, Heckman C. Novel Activating STAT5B Mutations As Drivers Of T-ALL Blood. 122: 3863-3863. DOI: 10.1182/Blood.V122.21.3863.3863 |
0.356 |
|
| 2013 |
Wennerberg K, Pemovska T, Kontro M, Yadav B, Kulesskiy E, Edgren H, Eldfors S, Karjalainen R, Venkata NPK, Lehto A, Majumder MM, Malani D, Murumägi A, Turunen L, Knowles J, et al. Abstract 65: Comprehensive ex vivo drug sensitivity testing combined with in depth molecular profiling of AML patients cells provides individualized treatment strategies and reveals mechanisms of drug resistance. Cancer Research. 73: 65-65. DOI: 10.1158/1538-7445.Am2013-65 |
0.402 |
|
| 2013 |
Eldfors S, Rajala HL, Ellonen P, Andersson EI, Lagström S, Almusa H, Edgren H, Lepistö M, Mattila P, Knowles J, Saarela J, Porkka K, Kallioniemi O, Mustjoki S, Heckman CA. Abstract 3164: Somatic mutation analysis pipeline for exome-sequencing data identifies oncogenic STAT3 mutations in T-LGL leukemia. Cancer Research. 73: 3164-3164. DOI: 10.1158/1538-7445.Am2013-3164 |
0.39 |
|
| 2013 |
Nyberg S, Hongisto V, Tadele DS, Edgren H, Leivonen S, Kallioniemi O, Mælandsmo GM, Perälä M, Børresen-Dale A, Sahlberg KK. Abstract 2107: Identification of alternative compounds by drug screening of HER2 positive breast cancer cell lines. Cancer Research. 73: 2107-2107. DOI: 10.1158/1538-7445.Am2013-2107 |
0.427 |
|
| 2012 |
Nikolaev SI, Sotiriou SK, Pateras IS, Santoni F, Sougioultzis S, Edgren H, Almusa H, Robyr D, Guipponi M, Saarela J, Gorgoulis VG, Antonarakis SE, Halazonetis TD. A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Research. 72: 6279-89. PMID 23204322 DOI: 10.1158/0008-5472.Can-12-3869 |
0.394 |
|
| 2012 |
Kangaspeska S, Hultsch S, Edgren H, Nicorici D, Murumägi A, Kallioniemi O. Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms. Plos One. 7: e48745. PMID 23119097 DOI: 10.1371/Journal.Pone.0048745 |
0.399 |
|
| 2012 |
Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. The New England Journal of Medicine. 366: 1905-13. PMID 22591296 DOI: 10.1056/Nejmoa1114885 |
0.336 |
|
| 2012 |
Högnäs G, Tuomi S, Veltel S, Mattila E, Murumägi A, Edgren H, Kallioniemi O, Ivaska J. Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. Oncogene. 31: 3597-606. PMID 22120710 DOI: 10.1038/Onc.2011.527 |
0.353 |
|
| 2012 |
Vainio P, Wolf M, Edgren H, He T, Kohonen P, Mpindi JP, Smit F, Verhaegh G, Schalken J, Perälä M, Iljin K, Kallioniemi O. Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. The Prostate. 72: 789-802. PMID 21919029 DOI: 10.1002/Pros.21487 |
0.44 |
|
| 2012 |
Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN, Basik M. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 31: 2090-100. PMID 21892209 DOI: 10.1038/Onc.2011.386 |
0.458 |
|
| 2012 |
Heckman CA, Kontro M, Pemovska T, Eldfors S, Edgren H, Kulesskiy E, Majumder MM, Karjalainen R, Yadav B, Szwajda A, Venkata NPK, Murumagi A, Malani D, Parsons A, Hintsanen P, et al. High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML Blood. 120: 288-288. DOI: 10.1182/Blood.V120.21.288.288 |
0.395 |
|
| 2012 |
Pemovska T, Kylesskiy E, Kontro M, Szwajda A, Karjalainen R, Majumder MM, Malani D, Bespalov MM, Eldfors S, Elonen E, Knowles J, Murumägi A, Mpindi JP, Edgren H, Venkata NPK, et al. Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance Cancer Research. 72: 895-895. DOI: 10.1158/1538-7445.Am2012-895 |
0.389 |
|
| 2012 |
Karjalainen R, Eldfors S, Edgren H, Venkata NPK, Kontro M, Majumder MM, Murumägi A, Parsons A, Almusa H, Ellonen P, Lepistö M, Mattila P, Hannula S, Lagström S, Suvela M, et al. Abstract 5067: Exome sequencing reveals both DNA sequence and copy number changes in AML: Potential driver changes and mechanisms of drug resistance revealed from serial samples from the same patients Cancer Research. 72: 5067-5067. DOI: 10.1158/1538-7445.Am2012-5067 |
0.476 |
|
| 2012 |
Venkata NPK, Kontro M, Edgren H, Eldfors S, Pemovska T, Kulesskiy E, Majumder MM, Murumägi A, Nicorici D, Almusa H, Mattila P, Ellonen P, Lepistö M, Mpindi JP, Karjalainen R, et al. Abstract 4580: Personalized treatment selection for therapy-resistant AML by integrating ex-vivo drug sensitivity and resistance testing (DSRT) as well as serial genomic, transcriptomic and phosphoproteomic profiling Cancer Research. 72: 4580-4580. DOI: 10.1158/1538-7445.Am2012-4580 |
0.445 |
|
| 2012 |
Malani D, Pemovska T, Kontro M, Murumägi A, Kulesskiy E, Yadav B, Bespalov M, Eldfors S, Elonen E, Karjalainen R, Knowles JK, Majumder MM, Mpindi JP, Edgren H, Szwajda A, et al. Abstract 3188: Development of a cancer pharmacopeia-wideex-vivodrug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns Cancer Research. 72: 3188-3188. DOI: 10.1158/1538-7445.Am2012-3188 |
0.427 |
|
| 2012 |
Majumder MM, Kontro M, Edgren H, Nicorici D, Parsons A, Karjalainen R, Eldfors S, Mattila P, Lepistö M, Ellonen P, Almusa H, Rintala H, Knowles JKc, Saarela J, Wennerberg K, et al. Abstract 3175: Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2 Cancer Research. 72: 3175-3175. DOI: 10.1158/1538-7445.Am2012-3175 |
0.328 |
|
| 2012 |
Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O. Erratum to: Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis Breast Cancer Research and Treatment. 131: 1085-1086. DOI: 10.1007/S10549-011-1654-4 |
0.342 |
|
| 2011 |
Edgren H, Kangaspeska S, Kallioniemi O. KRAS oncogene rearrangements and gene fusions: unexpected rare encounters in late-stage prostate cancers. Cancer Discovery. 1: 12-3. PMID 22586312 DOI: 10.1158/2159-8274.Cd-11-0045 |
0.365 |
|
| 2011 |
Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biology. 12: R6. PMID 21247443 DOI: 10.1186/Gb-2011-12-1-R6 |
0.482 |
|
| 2011 |
Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, Sara H, Guise T, Nees M, Kallioniemi O. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Research and Treatment. 125: 421-30. PMID 20352489 DOI: 10.1007/S10549-010-0848-5 |
0.418 |
|
| 2011 |
Koskela H, Eldfors S, Almusa H, Andersson E, Ellonen P, Edgren H, Koistinen P, Kuittinen T, Penttinen K, Knowles J, Saarela J, Kallioniemi O, Wennerberg K, Porkka K, Heckman C, et al. Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications Blood. 118: 936-936. DOI: 10.1182/Blood.V118.21.936.936 |
0.375 |
|
| 2011 |
Edgren H, Murumägi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Wolf M, Børresen-Dale A, Kallioniemi O. Abstract 4850: Paired-end RNA-sequencing based identification of 24 novel fusion genes in breast cancer Cancer Research. 71: 4850-4850. DOI: 10.1158/1538-7445.Am2011-4850 |
0.475 |
|
| 2011 |
Heckman C, Alitalo K, Andersson L, Campbell P, Edgren H, Futreal A, Holopainen T, Huang P, Joensuu H, Kallioniemi O, Kangaspeska S, Kilpinen S, Mandelin J, Monni O, Murumägi A, et al. Abstract 4836: In vitro drug sensitivity testing along with full genome and transcriptome sequencing and phosphoproteomics: Comprehensive “next-generation” molecular oncology portrait of a sarcoma for facilitating treatment decisions Cellular and Molecular Biology. DOI: 10.1158/1538-7445.Am2011-4836 |
0.301 |
|
| 2011 |
Chabot C, Mamo A, Cavallone L, Tuzmen S, Hassan S, Edgren H, Ferrario C, Aleynikova O, Przybytkowska E, Malcolm K, Kallioniemi O, Tonin P, Mousses S, Basik M. Abstract 4023: ARID1A is a candidate tumor suppressor gene in breast cancer Cellular and Molecular Biology. 71: 4023-4023. DOI: 10.1158/1538-7445.Am2011-4023 |
0.408 |
|
| 2010 |
Rantala JK, Edgren H, Lehtinen L, Wolf M, Kleivi K, Vollan HK, Aaltola AR, Laasola P, Kilpinen S, Saviranta P, Iljin K, Kallioniemi O. Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. Neoplasia (New York, N.Y.). 12: 877-88. PMID 21082043 DOI: 10.1593/Neo.10548 |
0.46 |
|
| 2010 |
McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hämäläinen E, Stebbings LA, Andersson LC, Flanagan AM, Durbecq V, Ignatiadis M, Kallioniemi O, Heckman CA, Alitalo K, ... Edgren H, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes, Chromosomes & Cancer. 49: 1062-9. PMID 20725990 DOI: 10.1002/Gcc.20815 |
0.367 |
|
| 2010 |
Wolf M, Korja M, Karhu R, Edgren H, Kilpinen S, Ojala K, Mousses S, Kallioniemi A, Haapasalo H. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. Bmc Cancer. 10: 181. PMID 20444257 DOI: 10.1186/1471-2407-10-181 |
0.341 |
|
| 2010 |
Main H, Lee KL, Yang H, Haapa-Paananen S, Edgren H, Jin S, Sahlgren C, Kallioniemi O, Poellinger L, Lim B, Lendahl U. Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. Experimental Cell Research. 316: 1610-24. PMID 20034489 DOI: 10.1016/J.Yexcr.2009.12.012 |
0.342 |
|
| 2010 |
Bjerkvig R, Leivonen SK, Ostling P, Aakula A, Kohonen P, Makela R, Hagman Z, Edgren H, Ceder Y, Perala M, Kallioniemi O. 558 Systematic functional analysis of microRNAs by transfection of 1129 miRNAs into prostate cancer cells Ejc Supplements. 8: 177-177. DOI: 10.1016/S1359-6349(10)72265-5 |
0.304 |
|
| 2009 |
Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5092-100. PMID 19671842 DOI: 10.1158/1078-0432.Ccr-08-3283 |
0.419 |
|
| 2009 |
Muggerud AA, Edgren H, Wolf M, Kleivi K, Dejeux E, Tost J, Sørlie T, Kallioniemi O. Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. Bmc Medical Genomics. 2: 26. PMID 19432969 DOI: 10.1186/1755-8794-2-26 |
0.448 |
|
| 2009 |
Koski TA, Lehtonen HJ, Jee KJ, Ninomiya S, Joosse SA, Vahteristo P, Kiuru M, Karhu A, Sammalkorpi H, Vanharanta S, Lehtonen R, Edgren H, Nederlof PM, Hietala M, Aittomäki K, et al. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes, Chromosomes & Cancer. 48: 544-51. PMID 19373782 DOI: 10.1002/Gcc.20663 |
0.359 |
|
| 2008 |
Pellinen T, Tuomi S, Arjonen A, Wolf M, Edgren H, Meyer H, Grosse R, Kitzing T, Rantala JK, Kallioniemi O, Fässler R, Kallio M, Ivaska J. Integrin trafficking regulated by Rab21 is necessary for cytokinesis. Developmental Cell. 15: 371-85. PMID 18804435 DOI: 10.1016/J.Devcel.2008.08.001 |
0.369 |
|
| 2008 |
Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, Saarela M, Skotheim RI, Björkman M, Mpindi JP, Haapa-Paananen S, Vainio P, Edgren H, Wolf M, et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biology. 9: R139. PMID 18803840 DOI: 10.1186/Gb-2008-9-9-R139 |
0.337 |
|
| 2007 |
Edgren H, Wolf M, Kallioniemi O, Nees M. Cancer genome analysis: a landscape seen from many angles Drug Discovery Today: Disease Mechanisms. 4: 269-276. DOI: 10.1016/J.Ddmec.2008.05.003 |
0.428 |
|
| 2006 |
Edgren H, Kallioniemi O. Integrated breast cancer genomics. Cancer Cell. 10: 453-4. PMID 17157784 DOI: 10.1016/J.Ccr.2006.11.007 |
0.451 |
|
| 2006 |
Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Research. 66: 10242-6. PMID 17079440 DOI: 10.1158/0008-5472.Can-06-1986 |
0.436 |
|
| 2005 |
Wolf M, Edgren H, Muggerud A, Kilpinen S, Huusko P, Sørlie T, Mousses S, Kallioniemi O. NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. Cellular Oncology : the Official Journal of the International Society For Cellular Oncology. 27: 169-73. PMID 16037637 DOI: 10.1155/2005/478316 |
0.478 |
|
| 2004 |
Berger JA, Hautaniemi S, Järvinen AK, Edgren H, Mitra SK, Astola J. Optimized LOWESS normalization parameter selection for DNA microarray data. Bmc Bioinformatics. 5: 194. PMID 15588297 DOI: 10.1186/1471-2105-5-194 |
0.3 |
|
| 2004 |
Järvinen AK, Hautaniemi S, Edgren H, Auvinen P, Saarela J, Kallioniemi OP, Monni O. Are data from different gene expression microarray platforms comparable? Genomics. 83: 1164-8. PMID 15177569 DOI: 10.1016/J.Ygeno.2004.01.004 |
0.378 |
|
| 2004 |
Kettunen E, Anttila S, Seppänen JK, Karjalainen A, Edgren H, Lindström I, Salovaara R, Nissén AM, Salo J, Mattson K, Hollmén J, Knuutila S, Wikman H. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genetics and Cytogenetics. 149: 98-106. PMID 15036884 DOI: 10.1016/S0165-4608(03)00300-5 |
0.377 |
|
| 2004 |
Hautaniemi S, Ringnér M, Kauraniemi P, Autio R, Edgren H, Yli-Harja O, Astola J, Kallioniemi A, Kallioniemi O. A strategy for identifying putative causes of gene expression variation in human cancers Journal of the Franklin Institute-Engineering and Applied Mathematics. 341: 77-88. DOI: 10.1016/J.Jfranklin.2003.12.005 |
0.44 |
|
| 2003 |
Nagy B, Lundán T, Larramendy ML, Aalto Y, Zhu Y, Niini T, Edgren H, Ferrer A, Vilpo J, Elonen E, Vettenranta K, Franssila K, Knuutila S. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. British Journal of Haematology. 120: 434-41. PMID 12580957 DOI: 10.1046/J.1365-2141.2003.04121.X |
0.319 |
|
| Show low-probability matches. |